Skip to content

Transpara

by Screenpoint Medical B.V.

510(k) K192287

Transpara is a X-ray image interpretive software (FDA Class II; FDA product code QDQ) made by Screenpoint Medical B.V., cleared under FDA 510(k) K192287 on 10 Dec 2019 and listed in FDA GUDID since 12 Dec 2019 (UDI-DI 08719326450124), active as of 10 Oct 2026.

Active United States. Also listed in GUDID (US).

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 10 Oct 2026

Documents

Trust

Unverified

Source FDA 510(k), GUDID, synced 10 Oct 2026.

Regulatory status

as of registry sync 10 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesGUDID listing GUDID Number08719326450124 UDI-DI Date12 Dec 2019ListedStatusListed GUDID: in commercial distribution
United StatesFDA 510(k)SESE 510(k) Substantially Equivalent · Traditional NumberK192287 Date10 Dec 2019ClearedStatusActive

Official records

From the FDA record

Received by the FDA
22 Aug 2019
FDA decision
10 Dec 2019 (Substantially Equivalent)
FDA review time
110 days from receipt to decision
Public document
510(k) summary on file with the FDA

From the FDA 510(k) record K192287 (openFDA), as read on 10 Oct 2026. Quoted as published, gaps included; nothing on this list is generated.

FDA GUDID

Device description
The ScreenPoint Transpara system is intended for use as a concurrent reading aid for physicians interpreting screening mammograms from compatible FFDM systems, to identify regions suspicious for breast cancer and assess their likelihood of malignancy. Output of the device includes marks placed on suspicious soft tissue lesions and suspicious calcifications, region based scores, displayed upon the physicians query, indicating the likelihood that cancer is present in specific regions, and an overall score indicating the likelihood that cancer is present on the mammogram. Patient management decisions should not be made solely on the basis of analysis by Transpara.
MRI safety
Labeling does not contain MRI Safety Information
Natural rubber latex
No latex statement on the label
Sterility
Supplied non-sterile

From the GUDID record (AccessGUDID), as read on 26 May 2026, as the labeller entered it.

Across registries

2 registries list this device

  • FDA 510(k) K192287 decided 10 Dec 2019 Active
  • FDA GUDID UDI-DI 08719326450124 listed 12 Dec 2019 Listed

Timeline

2 dated events

  1. Cleared FDA 510(k) K192287
  2. Listed FDA GUDID 08719326450124

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k) · GUDID

Generic name
X-ray image interpretive software
Model / reference
1.5.0 2D
Primary DI / UDI-DI
08719326450124
510(k) Number
FDA product code
QDQ
GMDN term
X-ray image interpretive software
Device class
Class II
Regulation
21 CFR Part 892.2090
Advisory committee
Radiology
FDA decision
SESE Substantially Equivalent
GUDID distribution status
In Commercial Distribution

Devices cleared under K192287

1 device · FDA GUDID

Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.

Devices cleared under K192287
UDI-DISize and differences
Transpara 1.5.0 2D
Screenpoint Medical B.V.
1.5.0 2D08719326450124 —On the market

Similar devices

Other devices filed under FDA product code QDQ (Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer).

Other devices from Screenpoint Medical B.V.

See all devices from Screenpoint Medical B.V. →

Properties

  • Prescription use
  • Lot / batch number
  • Serial number
Other properties (12, all answered No)